Trial Profile
A clinical study of the triplet combination of BXCL701, NKTR-214 and a checkpoint inhibitor for the treatment of patients with unresectable or metastatic pancreatic cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2018
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; Talabostat (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2018 New trial record